Each film-coated tablet also contains the following excipients: Cornstarch, lactose, povidone, talc and magnesium stearate.
Pharmacology: Diaglu is hypoglycaemic sulfonylurea which stimulates insulin secretion by the pancreas. Its action on insulin secretion is mainly due to the restoration of the early phase, resulting in physiological release of insulin. In addition to this pancreatic action, it has been demonstrated that Diaglu administration improves the metabolic utilization of glucose at a peripheral level. The extrapancreatic action is not due to a modification in the number of insulin receptors, but may be due to the potentiation of the post-receptor pathways. Thus, Diaglu restores glycaemic control throughout 24 hrs. It normalizes fasting and postprandial blood sugar.
In man, apart from having hypoglycaemic effect, Diaglu has been shown to reduce platelet hyperadhesiveness and hyperaggregation, and to increase fibrinolytic activity. These factors are thought to be implicated in the pathogenesis of the long-term complications of diabetes mellitus.
Controlled studies in patients with diabetic retinopathy suggest that these effects of Diaglu are beneficial in slowing down the progression of retinopathy.
Non-insulin dependent diabetes mellitus.
The total daily dose may vary from 1-4 tabs taken orally. The dose should be adjusted according to the individual patient's response, commencing with 40-80 mg daily and increasing until adequate control is achieved. A single dose should not exceed 160 mg and when higher doses are required, a twice-daily split dosage is advised and should be divided according to the main meals of the day.
In the majority of cases, 2 tabs/day with meals, 1 tab with breakfast, 1 tab with dinner.
For the elderly diabetic, the starting dose should be ½ tab in the evening.
Symptoms: The symptom to be expected is hypoglycaemia.
Treatment: Gastric lavage and correction of the hypoglycaemia by appropriate means with continued monitoring of the patient's blood sugar until the effect of gliclazide has ceased.
Hypersensitivity to other sulfonylureas and related drugs. Diaglu should not be used alone in insulin-dependent diabetes; diabetes complicated by ketosis and acidosis; diabetics undergoing surgery, after severe trauma or during infections.
Use in pregnancy: Diaglu should not be used during pregnancy.
Care should be exercised in patients with hepatic and/or renal impairment and a small starting dose should be used with careful patient monitoring. As with other sulfonylureas, hypoglycaemia will occur if the patient's dietary intake is reduced or if they are receiving a larger dose of Diaglu than required.
Use in pregnancy: Diaglu should not be used during pregnancy.
Diaglu is generally well-tolerated. Nausea, headache, rashes and gastrointestinal disturbances have been reported.
Immediately inform the physician of any adverse effects.
Potentiation of the hypoglycaemic action of Diaglu may occur with the concomitant administration of sulfonamides, salicylates, phenylbutazone, β-adrenoreceptor-blocking agents, monoamine oxidase inhibitors (MAOIs), ketoconazole and miconazole.
Diminution of hypoglycaemic action of Diaglu may occur with the concomitant administration of thiazide diuretics, corticosteroids and oestrogens.
Adjustment of dosage of hypoglycaemic agents may be required in patients suffering from intercurrent infections, traumas, shock or after anaesthesia.
When major surgery is to be performed, insulin therapy should be substituted for oral hypoglycaemics.
Do not administer if the color of the tablet has changed.
Store in air-tight, light-resistant container.
Shelf-Life: 3 years.
A10BB09 - gliclazide ; Belongs to the class of sulfonylureas. Used in the treatment of diabetes.
Tab 80 mg (white, round) x 10 x 10's.
Sign Out
